ArticleLife (Basel, Switzerland)2026
Comparative Evaluation of Systemic Inflammatory Indices in Bronchiectasis: Identification of Exacerbation Phenotype.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchiectasis is a heterogeneous chronic inflammatory airway disease characterized by recurrent exacerbations. Data on composite inflammatory biomarkers for assessing disease activity remain limited.
methodsThis retrospective study included 97 patients with non-cystic fibrosis bronchiectasis categorized as stable (n = 39) or with exacerbated bronchiectasis (n = 58). Demographic, clinical, and laboratory data were analyzed, and inflammatory indices-NLR (neutrophil-lymphocyte ratio), PLR (platelet-lymphocyte ratio), SII (Systemic Immune-Inflammation Index), PIV (Pan-Immune-Inflammation Value), CAR (C-reactive protein-to-albumin ratio), and HALP score (hemoglobin × albumin × lymphocyte/platelet)-were calculated, followed by multivariate logistic regression and ROC analyses.
resultsPatients with bronchiectasis exacerbations had a higher NLR, PLR, PIV, SII, and CAR and lower HALP (all
conclusionsComposite inflammatory indices are strongly associated with disease activity in bronchiectasis. CAR showed excellent discriminative performance, while HALP and SII independently predicted exacerbation. These simple, cost-effective biomarkers may support risk stratification and clinical monitoring in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.